The beneficial health effects of puerarin in the treatment of cardiovascular diseases: from mechanisms to therapeutics.

Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0326264 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1912 (Electronic) Linking ISSN: 00281298 NLM ISO Abbreviation: Naunyn Schmiedebergs Arch Pharmacol Subsets: MEDLINE

Original Publication: Berlin, New York, Springer Verlag.

Isoflavones*/therapeutic use ; Isoflavones*/pharmacology ; Cardiovascular Diseases*/drug therapy; Humans ; Animals ; Vasodilator Agents/therapeutic use ; Vasodilator Agents/pharmacology ; Vasodilator Agents/adverse effects ; Biological Availability

Cardiovascular diseases (CVDs) are the leading causes of death globally that seriously threaten human health. Although novel western medicines have continued to be discovered over the past few decades to inhibit the progression of CVDs, new drug research and development for treating CVDs with less side effects and adverse reactions are continuously being desired. Puerarin is a natural product found in a variety of medicinal plants belonging to the flavonoid family with potent biological and pharmacological activities. Abundant research findings in the literature have suggested that puerarin possesses a promising prospect in treating CVDs. In recent years, numerous new molecular mechanisms of puerarin have been explored in experimental and clinical studies, providing new evidence for this plant metabolite to protect against CVDs. This article systematically introduces the history of use, bioavailability, and various dosage forms of puerarin and further summarizes recently published data on the major research advances and their underlying therapeutic mechanisms in treating CVDs. It may provide references for researchers in the fields of pharmacology, natural products, and internal medicine.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)

Abouleisa RRE, Salama ABM, Ou Q, Tang XL, Solanki M, Guo Y, Nong Y, McNally L, Lorkiewicz PK, Kassem KM, Ahern BM, Choudhary K, Thomas R, Huang Y, Juhardeen HR, Siddique A, Ifthikar Z, Hammad SK, Elbaz AS, Ivey KN, Conklin DJ, Satin J, Hill BG, Srivastava D, Bolli R, Mohamed TMA (2022) Transient cell cycle induction in cardiomyocytes to treat subacute ischemic heart failure. Circulation 145:1339–1355. (PMID: 35061545903865010.1161/CIRCULATIONAHA.121.057641)
Aboushanab SA, Khedr SM, Gette IF, Danilova IG, Kolberg NA, Ravishankar GA, Ambati RR, Kovaleva EG (2023) Isoflavones derived from plant raw materials: bioavailability, anti-cancer, anti-aging potentials, and microbiome modulation. Crit Rev Food Sci Nutr 63:261–287. (PMID: 3425192110.1080/10408398.2021.1946006)
Ai F, Chen M, Yu B, Yang Y, Xu G, Gui F, Liu Z, Bai X, Chen Z (2015) Puerarin accelerate scardiac angiogenesis and improves cardiac function of myocardial infarction by upregulating VEGFA, Ang-1 and Ang-2 in rats. Int J Clin Exp Med 8:20821–20828. (PMID: 268850064723851)
Anukunwithaya T, Poo P, Hunsakunachai N, Rodsiri R, Malaivijitnond S, Khemawoot P (2018) Absolute oral bioavailability and disposition kinetics of puerarin in female rats. BMC Pharmacol Toxicol 19:25. (PMID: 29801513597053010.1186/s40360-018-0216-3)
Arnardottir H, Thul S, Pawelzik SC, Karadimou G, Artiach G, Gallina AL, Mysdotter V, Carracedo M, Tarnawski L, Caravaca AS, Baumgartner R, Ketelhuth DF, Olofsson PS, Paulsson-Berne G, Hansson GK, Back M (2021) The resolvin D1 receptor GPR32 transduces inflammation resolution and atheroprotection. J Clin Invest 131.
Attisano L, Wrana JL (2002) Signal transduction by the TGF-beta superfamily. Science 296:1646–1647. (PMID: 1204018010.1126/science.1071809)
Back M, Yurdagul A Jr, Tabas I, Oorni K, Kovanen PT (2019) Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol 16:389–406. (PMID: 308468756727648)
Bao MH, Zhang YW, Lou XY, Xiao Y, Cheng Y, Zhou HH (2014) Puerarin protects endothelial cells from oxidized low density lipoprotein induced injuries via the suppression of LOX-1 and induction of eNOS. Can J Physiol Pharmacol 92:299–306. (PMID: 2470821210.1139/cjpp-2013-0322)
Bao L, Zhang Y, Wei G, Wang Y, Ma R, Cheng R, Ren X, Agula B (2015) The anti-atherosclerotic effects of puerarin on induced-atherosclerosis in rabbits. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 159:53–59. (PMID: 2451011010.5507/bp.2013.096)
Cai SA, Hou N, Zhao GJ, Liu XW, He YY, Liu HL, Hua YQ, Li LR, Huang Y, Ou CW, Luo CF, Chen MS (2018) Nrf2 is a key regulator on puerarin preventing cardiac fibrosis and upregulating metabolic enzymes UGT1A1 in rats. Front Pharmacol 9:540. (PMID: 29928229599781110.3389/fphar.2018.00540)
Cai M, Zhuang W, Lv E, Liu Z, Wang Y, Zhang W, Fu W (2022) Kaemperfol alleviates pyroptosis and microglia-mediated neuroinflammation in Parkinson’s disease via inhibiting p38MAPK/NF-kappaB signaling pathway. Neurochem Int 152:105221. (PMID: 3478080610.1016/j.neuint.2021.105221)
Calleja P, Irache JM, Zandueta C, Martinez-Oharriz C, Espuelas S (2017) A combination of nanosystems for the delivery of cancer chemoimmunotherapeutic combinations: 1-methyltryptophan nanocrystals and paclitaxel nanoparticles. Pharmacol Res 126:77–83. (PMID: 2889362810.1016/j.phrs.2017.09.004)
Campos-Staffico AM, Freitas WM, Carvalho LSF, Coelho-Filho OR, Nadruz W Jr, Oliveira RB, Sposito AC, Brasilia Study on Healthy A, Brasilia Heart S (2020) Lower bone mass is associated with subclinical atherosclerosis, endothelial dysfunction and carotid thickness in the very elderly. Atherosclerosis 292:70–74. (PMID: 3178320010.1016/j.atherosclerosis.2019.11.007)
Cao Y, Xie L, Liu K, Liang Y, Dai X, Wang X, Lu J, Zhang X, Li X (2021) The antihypertensive potential of flavonoids from Chinese herbal medicine: a review. Pharmacol Res 174:105919. (PMID: 3460108010.1016/j.phrs.2021.105919)
Chambers KF, Day PE, Aboufarrag HT, Kroon PA (2019) Polyphenol effects on cholesterol metabolism via bile acid biosynthesis, CYP7A1: A Review. Nutrients 11.
Chang Y, Hsieh CY, Peng ZA, Yen TL, Hsiao G, Chou DS, Chen CM, Sheu JR (2009) Neuroprotective mechanisms of puerarin in middle cerebral artery occlusion-induced brain infarction in rats. J Biomed Sci 16:9. (PMID: 19272172265351110.1186/1423-0127-16-9)
Chang X, Zhang T, Liu D, Meng Q, Yan P, Luo D, Wang X, Zhou X (2021) Puerarin attenuates LPS-induced inflammatory responses and oxidative stress injury in human umbilical vein endothelial cells through mitochondrial quality control. Oxid Med Cell Longev 2021:6659240. (PMID: 33728025793747410.1155/2021/6659240)
Chaumont C, Suffee N, Gandjbakhch E, Balse E, Anselme F, Hatem SN (2022) Epicardial origin of cardiac arrhythmias: clinical evidences and pathophysiology. Cardiovasc Res 118:1693–1702. (PMID: 3415239210.1093/cvr/cvab213)
Chen R, Xue J, Xie M (2012) Puerarin prevents isoprenaline-induced myocardial fibrosis in mice by reduction of myocardial TGF-beta1 expression. J Nutr Biochem 23:1080–1085. (PMID: 2207920510.1016/j.jnutbio.2011.05.015)
Chen G, Pan SQ, Shen C, Pan SF, Zhang XM, He QY (2014) Puerarin inhibits angiotensin II-induced cardiac hypertrophy via the redox-sensitive ERK1/2, p38 and NF-kappaB pathways. Acta Pharmacol Sin 35:463–475. (PMID: 2460867310.1038/aps.2013.185)
Chen T, Liu W, Xiong S, Li D, Fang S, Wu Z, Wang Q, Chen X (2019) Nanoparticles mediating the sustained puerarin release facilitate improved brain delivery to treat Parkinson’s disease. ACS Appl Mater Interfaces 11:45276–45289. (PMID: 3163877110.1021/acsami.9b16047)
Chen M, Xiang L, Wu G, Liao Y, Cai Y (2020a) Puerarin inhibits endothelium-dependent contractions in mouse carotid arteries. Med Sci Monit 26:e923163. (PMID: 32555127)
Chen M, Zhou C, Xu H, Zhang T, Wu B (2020b) Chronopharmacological targeting of Rev-erbalpha by puerarin alleviates hyperhomocysteinemia in mice. Biomed Pharmacother 125:109936. (PMID: 3200690310.1016/j.biopha.2020.109936)
Chen F, Chen ZQ, Wang H, Zhu JJ (2021a) Puerarin pretreatment inhibits myocardial apoptosis and improves cardiac function in rats after acute myocardial infarction through the PI3K/Akt signaling pathway. Adv Clin Exp Med 30:255–261. (PMID: 3376874010.17219/acem/131754)
Chen ZQ, Zhou Y, Huang JW, Chen F, Zheng J, Li HL, Li T, Li L (2021b) Puerarin pretreatment attenuates cardiomyocyte apoptosis induced by coronary microembolization in rats by activating the PI3K/Akt/GSK-3beta signaling pathway. Korean J Physiol Pharmacol 25:147–157. (PMID: 3360288510.4196/kjpp.2021.25.2.147)
Cheng M, Li X, Guo Z, Cui X, Li H, Jin C, Zhang X, Guan X (2013) Puerarin accelerates re-endothelialization in a carotid arterial injury model: impact on vasodilator concentration and vascular cell functions. J Cardiovasc Pharmacol 62:361–368. (PMID: 2379270210.1097/FJC.0b013e31829dd961)
Cheng W, Wu P, Du Y, Wang Y, Zhou N, Ge Y, Yang Z (2015) Puerarin improves cardiac function through regulation of energy metabolism in Streptozotocin-Nicotinamide induced diabetic mice after myocardial infarction. Biochem Biophys Res Commun 463:1108–1114. (PMID: 2607988510.1016/j.bbrc.2015.06.067)
Cheng M, Yuan F, Liu J, Liu W, Feng J, Jin Y, Tu L (2020) Fabrication of fine puerarin nanocrystals by Box-Behnken design to enhance intestinal absorption. AAPS PharmSciTech 21:90. (PMID: 3206065410.1208/s12249-019-1616-4)
Chi X, Fan Q, Zhang Y, Liang K, Wan L, Zhou Q, Li Y (2020) Structural mechanism of phospholipids translocation by MlaFEDB complex. Cell Res 30:1127–1135. (PMID: 32884137778468910.1038/s41422-020-00404-6)
Cho HJ, Jun HJ, Lee JH, Jia Y, Hoang MH, Shim JH, Park KH, Lee SJ (2012) Acute effect of high-dose isoflavones from Pueraria lobata (Willd.) Ohwi on lipid and bone metabolism in ovariectomized mice. Phytother Res 26:1864–1871. (PMID: 2242266110.1002/ptr.4669)
Chung MJ, Sung NJ, Park CS, Kweon DK, Mantovani A, Moon TW, Lee SJ, Park KH (2008) Antioxidative and hypocholesterolemic activities of water-soluble puerarin glycosides in HepG2 cells and in C57 BL/6J mice. Eur J Pharmacol 578:159–170. (PMID: 1797657310.1016/j.ejphar.2007.09.036)
Colmorten KB, Nexoe AB, Sorensen GL (2019) The dual role of surfactant protein-D in vascular inflammation and development of cardiovascular disease. Front Immunol 10:2264. (PMID: 3161643510.3389/fimmu.2019.02264)
Cui S, Zhao C, Tang X, Chen D, He Z (2005) Study on the bioavailability of puerarin from Pueraria lobata isoflavone self-microemulsifying drug-delivery systems and tablets in rabbits by liquid chromatography-mass spectrometry. Biomed Chromatogr 19:375–378. (PMID: 1562727810.1002/bmc.460)
De Meyer SF, Langhauser F, Haupeltshofer S, Kleinschnitz C, Casas AI (2022) Thromboinflammation in brain ischemia: recent updates and future perspectives. Stroke 53:1487–1499. (PMID: 3536093110.1161/STROKEAHA.122.038733)
Deng Y, Ng ES, Yeung JH, Kwan YW, Lau CB, Koon JC, Zhou L, Zuo Z, Leung PC, Fung KP, Lam FF (2012) Mechanisms of the cerebral vasodilator actions of isoflavonoids of Gegen on rat isolated basilar artery. J Ethnopharmacol 139:294–304. (PMID: 2212001710.1016/j.jep.2011.11.021)
Deng HF, Wang XL, Sun H, Xiao XZ (2017) Puerarin inhibits expression of tissue factor induced by oxidative low-density lipoprotein through activating the PI3K/Akt/eNOS pathway and inhibiting activation of ERK1/2 and NF-kappaB. Life Sci 191:115–121. (PMID: 2903784210.1016/j.lfs.2017.10.018)
Deng HF, Wang S, Li L, Zhou Q, Guo WB, Wang XL, Liu MD, Liu K, Xiao XZ (2018a) Puerarin prevents vascular endothelial injury through suppression of NF-kappaB activation in LPS-challenged human umbilical vein endothelial cells. Biomed Pharmacother 104:261–267. (PMID: 2977589310.1016/j.biopha.2018.05.038)
Deng Y, Lei T, Li H, Mo X, Wang Z, Ou H (2018b) ERK5/KLF2 activation is involved in the reducing effects of puerarin on monocyte adhesion to endothelial cells and atherosclerotic lesion in apolipoprotein E-deficient mice. Biochim Biophys Acta Mol Basis Dis 1864:2590–2599. (PMID: 2972369810.1016/j.bbadis.2018.04.021)
Deng HF, Wang S, Wang XL, Li L, Xie F, Zeng ZW, Zhang WX (2019) Puerarin protects against LPS-induced vascular endothelial cell hyperpermeability via preventing downregulation of endothelial cadherin. Inflammation 42:1504–1510. (PMID: 3110212310.1007/s10753-019-01014-0)
Dimmeler S, Haendeler J, Galle J, Zeiher AM (1997) Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. A mechanistic clue to the ‘response to injury’ hypothesis. Circulation 95:1760–1763. (PMID: 910715910.1161/01.CIR.95.7.1760)
Ding D, Zhu Q (2018) Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics. Mater Sci Eng C Mater Biol Appl 92:1041–1060. (PMID: 3018472810.1016/j.msec.2017.12.036)
Ding X, Xiang W, He X (2020a) IFN-I mediates dysfunction of endothelial progenitor cells in atherosclerosis of systemic lupus erythematosus. Front Immunol 11:581385. (PMID: 33262760768651110.3389/fimmu.2020.581385)
Ding Z, Wang X, Liu S, Zhou S, Kore RA, Mu S, Deng X, Fan Y, Mehta JL (2020b) NLRP3 inflammasome via IL-1beta regulates PCSK9 secretion. Theranostics 10:7100–7110. (PMID: 3264198110.7150/thno.45939)
Ding Y, Li W, Peng S, Zhou G, Chen S, Wei Y, Xu J, Gu H, Li J, Liu S, Liu B (2023) Puerarin protects against myocardial ischemia/reperfusion injury by inhibiting ferroptosis. Biol Pharm Bull 46:524–532. (PMID: 3669698910.1248/bpb.b22-00174)
Dong Z, Guo J, Xing X, Zhang X, Du Y, Lu Q (2017) RGD modified and PEGylated lipid nanoparticles loaded with puerarin: formulation, characterization and protective effects on acute myocardial ischemia model. Biomed Pharmacother 89:297–304. (PMID: 2823670310.1016/j.biopha.2017.02.029)
Eckle T, Bertazzo J, Khatua TN, Fatemi Tabatabaei SR, Moori Bakhtiari N, Walker LA, Martino TA (2024) Circadian influences on myocardial ischemia-reperfusion injury and heart failure. Circ Res 134:675–694. (PMID: 3848402410.1161/CIRCRESAHA.123.323522)
Endres M, Moro MA, Nolte CH, Dames C, Buckwalter MS, Meisel A (2022) Immune pathways in etiology, acute phase, and chronic sequelae of ischemic stroke. Circ Res 130:1167–1186. (PMID: 3542091510.1161/CIRCRESAHA.121.319994)
Fang X, Dong S, Wu Y, He Y, Lu M, Shi D, Feng N, Yin S, Jiang Y, Zhang A, Ding Y, Zhang Q, Tang J, Zhang W, He X (2021a) Ameliorated biomechanical properties of carotid arteries by puerarin in spontaneously hypertensive rats. BMC Complement Med Ther 21:173. (PMID: 3415457510.1186/s12906-021-03345-8)
Fang X, Zhang K, Jiang M, Ma L, Liu J, Xu H, Yang Y, Wang C (2021b) Enhanced lymphatic delivery of nanomicelles encapsulating CXCR4-recognizing peptide and doxorubicin for the treatment of breast cancer. Int J Pharm 594:120183. (PMID: 3334059610.1016/j.ijpharm.2020.120183)
Finocchiaro G, Westaby J, Sheppard MN, Papadakis M, Sharma S (2024) Sudden cardiac death in young athletes: JACC state-of-the-art review. J Am Coll Cardiol 83:350–370. (PMID: 3819971310.1016/j.jacc.2023.10.032)
Fredman G, MacNamara KC (2021) Atherosclerosis is a major human killer and non-resolving inflammation is a prime suspect. Cardiovasc Res 117:2563–2574. (PMID: 346095058783387)
Fu C, Chen B, Jin X, Liu X, Wang F, Guo R, Chen Z, Zheng H, Wang L, Zhang Y (2018) Puerarin protects endothelial progenitor cells from damage of angiotensin II via activation of ERK1/2Nrf2 signaling pathway. Mol Med Rep 17:3877–3883. (PMID: 29359784)
Fu Y, Qin C, Gao S, Lv C, Zhang C, Yao Y (2022) Aquifer flushing using a SDS/1-butanol based in-situ microemulsion: performance and mechanism for the remediation of nitrobenzene contamination. J Hazard Mater 424:127409. (PMID: 3462919610.1016/j.jhazmat.2021.127409)
Gac P, Martuszewski A, Paluszkiewicz P, Poreba M, Mazur G, Poreba R (2021) Aortic valve calcification score in patients with arterial hypertension environmentally exposed to tobacco smoke. Cardiovasc Toxicol 21:869–879. (PMID: 34309797847872410.1007/s12012-021-09677-8)
Gang C, Qiang C, Xiangli C, Shifen P, Chong S, Lihong L (2015) Puerarin suppresses angiotensin II-induced cardiac hypertrophy by inhibiting NADPH oxidase activation and oxidative stress-triggered AP-1 signaling pathways. J Pharm Pharm Sci 18:235–248. (PMID: 2615828810.18433/J3N318)
Gao Q, Pan HY, Qiu S, Lu Y, Bruce IC, Luo JH, Xia Q (2006) Atractyloside and 5-hydroxydecanoate block the protective effect of puerarin in isolated rat heart. Life Sci 79:217–224. (PMID: 1645832610.1016/j.lfs.2005.12.040)
Gao Q, Yang B, Ye ZG, Wang J, Bruce IC, Xia Q (2007) Opening the calcium-activated potassium channel participates in the cardioprotective effect of puerarin. Eur J Pharmacol 574:179–184. (PMID: 1769231110.1016/j.ejphar.2007.07.018)
Gao Y, Wang X, He C (2016) An isoflavonoid-enriched extract from Pueraria lobata (kudzu) root protects human umbilical vein endothelial cells against oxidative stress induced apoptosis. J Ethnopharmacol 193:524–530. (PMID: 2771790310.1016/j.jep.2016.10.005)
Gao S, Li L, Li L, Ni J, Guo R, Mao J, Fan G (2019) Effects of the combination of tanshinone IIA and puerarin on cardiac function and inflammatory response in myocardial ischemia mice. J Mol Cell Cardiol 137:59–70. (PMID: 3162973510.1016/j.yjmcc.2019.09.012)
Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S, Magee LA, Rana S, Vermunt JV, August P, American Heart Association Council on H, Council on the Kidney in Cardiovascular Disease KiHDSC, Council on Arteriosclerosis T, Vascular B, Council on L, Cardiometabolic H, Council on Peripheral Vascular D, Stroke C (2022) Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association. Hypertension 79: e21-e41.
Gem JB, Kovacs KB, Szalai L, Szakadati G, Porkolab E, Szalai B, Turu G, Toth AD, Szekeres M, Hunyady L, Balla A (2021) Characterization of type 1 angiotensin ii receptor activation induced dual-specificity MAPK phosphatase gene expression changes in rat vascular smooth muscle cells. Cells 10.
Gouveia L, Betsholtz C, Andrae J (2018) PDGF-A signaling is required for secondary alveolar septation and controls epithelial proliferation in the developing lung. Development 145.
Grebe A, Hoss F, Latz E (2018) NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ Res 122:1722–1740. (PMID: 2988050010.1161/CIRCRESAHA.118.311362)
Guan L, Li C, Zhang Y, Gong J, Wang G, Tian P, Shen N (2020) Puerarin ameliorates retinal ganglion cell damage induced by retinal ischemia/reperfusion through inhibiting the activation of TLR4/NLRP3 inflammasome. Life Sci 256:117935. (PMID: 3252628610.1016/j.lfs.2020.117935)
Guo BQ, Xu JB, Xiao M, Ding M, Duan LJ (2018) Puerarin reduces ischemia/reperfusion-induced myocardial injury in diabetic rats via upregulation of vascular endothelial growth factor A/angiotensin-1 and suppression of apoptosis. Mol Med Rep 17:7421–7427. (PMID: 29568939)
Hammoud Z, Gharib R, Fourmentin S, Elaissari A, Greige-Gerges H (2020) Drug-in-hydroxypropyl-beta-cyclodextrin-in-lipoid S100/cholesterol liposomes: effect of the characteristics of essential oil components on their encapsulation and release. Int J Pharm 579:119151. (PMID: 3207076110.1016/j.ijpharm.2020.119151)
Han Q, Chen K, Su C, Liu X, Luo X (2021) Puerarin loaded PLGA nanoparticles: optimization processes of preparation and anti-alcohol intoxication effects in Mice. AAPS PharmSciTech 22:217. (PMID: 3438683210.1208/s12249-021-02092-w)
Harada-Shiba M, Kinoshita M, Kamido H, Shimokado K (1998) Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms. J Biol Chem 273:9681–9687. (PMID: 954530210.1074/jbc.273.16.9681)
He L, Wang T, Chen BW, Lu FM, Xu J (2019) Puerarin inhibits apoptosis and inflammation in myocardial cells via PPARalpha expression in rats with chronic heart failure. Exp Ther Med 18:3347–3356. (PMID: 316022086777288)
He L, Guo C, Peng C, Li Y (2021) Advances of natural activators for Nrf2 signaling pathway on cholestatic liver injury protection: a review. Eur J Pharmacol 910:174447. (PMID: 3446112610.1016/j.ejphar.2021.174447)
He W, McCarroll CS, Nather K, Ford K, Mangion K, Riddell A, O’Toole D, Zaeri A, Corcoran D, Carrick D, Lee MMY, McEntegart M, Davie A, Good R, Lindsay MM, Eteiba H, Rocchiccioli P, Watkins S, Hood S, Shaukat A, McArthur L, Elliott EB, McClure J, Hawksby C, Martin T, Petrie MC, Oldroyd KG, Smith GL, Infarction OAM, S, Channon KM, Berry C, Nicklin SA, Loughrey CM, (2022) Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size. Cardiovasc Res 118:1535–1547. (PMID: 3413280710.1093/cvr/cvab204)
Heller HC (2021) Astrocytes are more dynamic players in brain functions than previously recognized. Sleep Med Rev 59:101520. (PMID: 3442537610.1016/j.smrv.2021.101520)
Hettwer J, Hinterdobler J, Miritsch B, Deutsch MA, Li X, Mauersberger C, Moggio A, Braster Q, Gram H, Robertson AAB, Cooper MA, Gross O, Krane M, Weber C, Koenig W, Soehnlein O, Adamstein NH, Ridker P, Schunkert H, Libby P, Kessler T, Sager HB (2022) Interleukin-1beta suppression dampens inflammatory leucocyte production and uptake in atherosclerosis. Cardiovasc Res 118:2778–2791. (PMID: 3471844410.1093/cvr/cvab337)
Heusch G (2020) Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol 17:773–789. (PMID: 3262085110.1038/s41569-020-0403-y)
Heusch G (2022) Coronary blood flow in heart failure: cause, consequence and bystander. Basic Res Cardiol 117:1. (PMID: 35024969875865410.1007/s00395-022-00909-8)
Hirota T, Fujita Y, Ieiri I (2020) An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol 16:809–822. (PMID: 3272974610.1080/17425255.2020.1801634)
Home P, Itzhak B (2020) Is insulin therapy safe? Am J Ther 27:e106–e114. (PMID: 3156719710.1097/MJT.0000000000001077)
Hong FF, Liang XY, Liu W, Lv S, He SJ, Kuang HB, Yang SL (2019) Roles of eNOS in atherosclerosis treatment. Inflamm Res 68:429–441. (PMID: 3093746610.1007/s00011-019-01229-9)
Hopman L, Mulder MJ, van der Laan AM, Demirkiran A, Bhagirath P, van Rossum AC, Allaart CP, Gotte MJW (2021) Impaired left atrial reservoir and conduit strain in patients with atrial fibrillation and extensive left atrial fibrosis. J Cardiovasc Magn Reson 23:131. (PMID: 34758820858218410.1186/s12968-021-00820-6)
Hou N, Cai B, Ou CW, Zhang ZH, Liu XW, Yuan M, Zhao GJ, Liu SM, Xiong LG, Luo JD, Luo CF, Chen MS (2017) Puerarin-7-O-glucuronide, a water-soluble puerarin metabolite, prevents angiotensin II-induced cardiomyocyte hypertrophy by reducing oxidative stress. Naunyn Schmiedebergs Arch Pharmacol 390:535–545. (PMID: 2821075310.1007/s00210-017-1353-8)
Hou N, Huang Y, Cai SA, Yuan WC, Li LR, Liu XW, Zhao GJ, Qiu XX, Li AQ, Cheng CF, Liu SM, Chen XH, Cai DF, Xie JX, Chen MS, Luo CF (2021) Puerarin ameliorated pressure overload-induced cardiac hypertrophy in ovariectomized rats through activation of the PPARalpha/PGC-1 pathway. Acta Pharmacol Sin 42:55–67. (PMID: 3250406610.1038/s41401-020-0401-y)
Hu W, Zhang Q, Yang X, Wang Y, Sun L (2010) Puerarin inhibits adhesion molecule expression in tnf-alpha-stimulated human endothelial cells via modulation of the nuclear factor kappaB pathway. Pharmacology 85:27–35. (PMID: 2001624510.1159/000264938)
Hu W, Yang X, Zhe C, Zhang Q, Sun L, Cao K (2011) Puerarin inhibits iNOS, COX-2 and CRP expression via suppression of NF-kappaB activation in LPS-induced RAW264.7 macrophage cells. Pharmacol Rep 63:781–789. (PMID: 2185708910.1016/S1734-1140(11)70590-4)
Hu Y, Liu K, Bo S, Yan M, Zhang Y, Miao C, Ren L (2016) Inhibitory effect of puerarin on vascular smooth muscle cells proliferation induced by oxidised low-density lipoprotein via suppressing ERK 1/2 phosphorylation and PCNA expression. Pharmazie 71:89–93. (PMID: 27004373)
Hu Y, Li H, Li R, Wu Z, Yang W, Qu W (2020) Puerarin protects vascular smooth muscle cells from oxidized low-density lipoprotein-induced reductions in viability via inhibition of the p38 MAPK and JNK signaling pathways. Exp Ther Med 20:270. (PMID: 33199995766459610.3892/etm.2020.9400)
Hu J, Tan X, Wang D, Li Y, Liang H, Peng J, Li F, Zhou Q, Geng P, Wang S, Yu Y, Liu J (2021) A stepwise-targeting strategy for the treatment of cerebral ischemic stroke. J Nanobiotechnology 19:371. (PMID: 34789285860069510.1186/s12951-021-01118-6)
Hwang YP, Kim HG, Hien TT, Jeong MH, Jeong TC, Jeong HG (2011) Puerarin activates endothelial nitric oxide synthase through estrogen receptor-dependent PI3-kinase and calcium-dependent AMP-activated protein kinase. Toxicol Appl Pharmacol 257:48–58. (PMID: 2188471710.1016/j.taap.2011.08.017)
Ji L, Du Q, Li Y, Hu W (2016) Puerarin inhibits the inflammatory response in atherosclerosis via modulation of the NF-kappaB pathway in a rabbit model. Pharmacol Rep 68:1054–1059. (PMID: 2750585510.1016/j.pharep.2016.06.007)
Ji XK, Madhurapantula SV, He G, Wang KY, Song CH, Zhang JY, Wang KJ (2021) Genetic variant of cyclooxygenase-2 in gastric cancer: more inflammation and susceptibility. World J Gastroenterol 27:4653–4666. (PMID: 34366627832626110.3748/wjg.v27.i28.4653)
Jiang L, Dai J, Huang Z, Du Q, Lin J, Wang Y (2013) Simultaneous determination of gastrodin and puerarin in rat plasma by HPLC and the application to their interaction on pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci 915–916:8–12. (PMID: 2331448810.1016/j.jchromb.2012.12.011)
Jiang Z, Cui X, Qu P, Shang C, Xiang M, Wang J (2022) Roles and mechanisms of puerarin on cardiovascular diseaseA review. Biomed Pharmacother 147:112655. (PMID: 3506629910.1016/j.biopha.2022.112655)
Jin YG, Yuan Y, Wu QQ, Zhang N, Fan D, Che Y, Wang ZP, Xiao Y, Wang SS, Tang QZ (2017) Puerarin protects against cardiac fibrosis associated with the inhibition of TGF-beta1/Smad2-mediated endothelial-to-mesenchymal transition. PPAR Res 2017:2647129. (PMID: 28638404546859410.1155/2017/2647129)
Jordan J, Ricci F, Hoffmann F, Hamrefors V, Fedorowski A (2020) Orthostatic hypertension: critical appraisal of an overlooked condition. Hypertension 75:1151–1158. (PMID: 3222338210.1161/HYPERTENSIONAHA.120.14340)
Keller M, Mirakaj V, Koeppen M, Rosenberger P (2021) Neuronal guidance proteins in cardiovascular inflammation. Basic Res Cardiol 116:6. (PMID: 33511463784324110.1007/s00395-021-00847-x)
Kim J, Becker RC (2016) Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events. J Thromb Thrombolysis 41:493–504. (PMID: 2673931310.1007/s11239-015-1307-2)
Knowles JW, Reddick RL, Jennette JC, Shesely EG, Smithies O, Maeda N (2000) Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. J Clin Invest 105:451–458. (PMID: 1068337428916010.1172/JCI8376)
Kropfl JM (2021) Circulating progenitor cells as predictor of mortality in cardiovascular disease: could physical activity change the global outcome? Atherosclerosis 333:83–84. (PMID: 3439157210.1016/j.atherosclerosis.2021.08.001)
Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD (1990) Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344:160–162. (PMID: 210662710.1038/344160a0)
Kwon YN, Kim YJ (2021) Gut-brain-microbiota axis and hypertension: a literature review. Curr Pharm Des 27:3939–3946. (PMID: 3472785310.2174/1381612827666210706161733)
Lara-Guzman OJ, Gil-Izquierdo A, Medina S, Osorio E, Alvarez-Quintero R, Zuluaga N, Oger C, Galano JM, Durand T, Munoz-Durango K (2018) Oxidized LDL triggers changes in oxidative stress and inflammatory biomarkers in human macrophages. Redox Biol 15:1–11. (PMID: 2919513610.1016/j.redox.2017.11.017)
Lecce L, Xu Y, V'Gangula B, Chandel N, Pothula V, Caudrillier A, Santini MP, d'Escamard V, Ceholski DK, Gorski PA, Ma L, Koplev S, Bjorklund MM, Bjorkegren JL, Boehm M, Bentzon JF, Fuster V, Kim HW, Weintraub NL, Baker AH, Bernstein E, Kovacic JC (2021) Histone deacetylase 9 promotes endothelial-mesenchymal transition and an unfavorable atherosclerotic plaque phenotype. J Clin Invest 131.
Li Y, Pan WS, Chen SL, Xu HX, Yang DJ, Chan AS (2006) Pharmacokinetic, tissue distribution, and excretion of puerarin and puerarin-phospholipid complex in rats. Drug Dev Ind Pharm 32:413–422. (PMID: 1663867910.1080/03639040600559123)
Li Y, Yang DJ, Chen SL, Chen SB, Chan AS (2008) Process parameters and morphology in puerarin, phospholipids and their complex microparticles generation by supercritical antisolvent precipitation. Int J Pharm 359:35–45. (PMID: 1844073610.1016/j.ijpharm.2008.03.022)
Li T, Matozel M, Boehme S, Kong B, Nilsson LM, Guo G, Ellis E, Chiang JY (2011) Overexpression of cholesterol 7alpha-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis. Hepatology 53:996–1006. (PMID: 2131919110.1002/hep.24107)
Li J, Liu P, Liu JP, Yang JK, Zhang WL, Fan YQ, Kan SL, Cui Y, Zhang WJ (2013) Bioavailability and foam cells permeability enhancement of Salvianolic acid B pellets based on drug-phospholipids complex technique. Eur J Pharm Biopharm 83:76–86. (PMID: 2308558210.1016/j.ejpb.2012.09.021)
Li R, Song J, Wu W, Wu X, Su M (2016) Puerarin exerts the protective effect against chemical induced dysmetabolism in rats. Gene 595:168–174. (PMID: 2767722110.1016/j.gene.2016.09.036)
Li CH, Gong D, Chen LY, Zhang M, Xia XD, Cheng HP, Huang C, Zhao ZW, Zheng XL, Tang XE, Tang CK (2017a) Puerarin promotes ABCA1-mediated cholesterol efflux and decreases cellular lipid accumulation in THP-1 macrophages. Eur J Pharmacol 811:74–86. (PMID: 2857640610.1016/j.ejphar.2017.05.055)
Li W, Lu M, Zhang Y, Xia D, Chen Z, Wang L, Yin N, Wang Z (2017b) Puerarin attenuates the daunorubicin-induced apoptosis of H9c2 cells by activating the PI3K/Akt signaling pathway via the inhibition of Ca2+ influx. Int J Mol Med 40:1889–1894. (PMID: 29039532)
Li X, Lin Y, Zhou H, Li Y, Wang A, Wang H, Zhou MS (2017c) Puerarin protects against endothelial dysfunction and end-organ damage in Ang II-induced hypertension. Clin Exp Hypertens 39:58–64. (PMID: 2806054210.1080/10641963.2016.1200603)
Li WQ, Wu JY, Xiang DX, Luo SL, Hu XB, Tang TT, Sun TL, Liu XY (2019a) Micelles loaded with puerarin and modified with triphenylphosphonium cation possess mitochondrial targeting and demonstrate enhanced protective effect against isoprenaline-induced H9c2 cells apoptosis. Int J Nanomedicine 14:8345–8360. (PMID: 31695371681431710.2147/IJN.S219670)
Li XF, Yuan T, Xu H, Xin X, Zhao G, Wu H, Xiao X (2019b) Whole-cell catalytic synthesis of puerarin monoesters and analysis of their antioxidant activities. J Agric Food Chem 67:299–307. (PMID: 3055841410.1021/acs.jafc.8b05805)
Li X, Sun S, Chen D, Yuan T, Chen Y, Wang D, Fang L, Lu Y, Du G (2020) Puerarin attenuates the endothelial-mesenchymal transition induced by oxidative stress in human coronary artery endothelial cells through PI3K/AKT pathway. Eur J Pharmacol 886:173472. (PMID: 3286080910.1016/j.ejphar.2020.173472)
Li C, Lin L, Zhang L, Xu R, Chen X, Ji J, Li Y (2021a) Long noncoding RNA p21 enhances autophagy to alleviate endothelial progenitor cells damage and promote endothelial repair in hypertension through SESN2/AMPK/TSC2 pathway. Pharmacol Res 173:105920. (PMID: 3460108110.1016/j.phrs.2021.105920)
Li W, Hu H, Zou G, Ma Z, Liu J, Li F (2021b) Therapeutic effects of puerarin on polycystic ovary syndrome: a randomized trial in Chinese women. Medicine (baltimore) 100:e26049. (PMID: 3403273110.1097/MD.0000000000026049)
Li W, Xu X, Dong D, Lei T, Ou H (2021c) Up-regulation of thioredoxin system by puerarin inhibits lipid uptake in macrophages. Free Radic Biol Med 162:542–554. (PMID: 3324260610.1016/j.freeradbiomed.2020.11.011)
Li Y, Guo X, Xue G, Wang H, Wang Y, Wang W, Yang S, Ni Q, Chen J, Lv L, Zhao Y, Ye M, Zhang L (2021d) RNA splicing of the Abi1 gene by MBNL1 contributes to macrophage-like phenotype modulation of vascular smooth muscle cell during atherogenesis. Cell Prolif 54:e13023. (PMID: 33759281808846110.1111/cpr.13023)
Li J, Li Y, Yuan X, Yao D, Gao Z, Niu Z, Wang Z, Zhang Y (2023) The effective constituent puerarin, from Pueraria lobata, inhibits the proliferation and inflammation of vascular smooth muscle in atherosclerosis through the miR-29b-3p/IGF1 pathway. Pharm Biol 61:1–11. (PMID: 3653731610.1080/13880209.2022.2099430)
Li X, Yuan T, Chen D, Chen Y, Sun S, Wang D, Fang L, Lu Y, Du G (2018) Cardioprotective effects of puerarin-V on isoproterenol-induced myocardial infarction mice is associated with regulation of PPAR-Upsilon/NF-kappaB pathway. Molecules 23.
Lian D, Yuan H, Yin X, Wu Y, He R, Huang Y, Chen Y (2019) Puerarin inhibits hyperglycemia-induced inter-endothelial junction through suppressing endothelial Nlrp3 inflammasome activation via ROS-dependent oxidative pathway. Phytomedicine 55:310–319. (PMID: 3038513410.1016/j.phymed.2018.10.013)
Liao L, Starzyk RM, Granger DN (1997) Molecular determinants of oxidized low-density lipoprotein-induced leukocyte adhesion and microvascular dysfunction. Arterioscler Thromb Vasc Biol 17:437–444. (PMID: 910216110.1161/01.ATV.17.3.437)
Libby P (2021) Inflammation during the life cycle of the atherosclerotic plaque. Cardiovasc Res 117:2525–2536. (PMID: 345503378783385)
Lim HY, Lim SY, Tan CK, Thiam CH, Goh CC, Carbajo D, Chew SHS, See P, Chakarov S, Wang XN, Lim LH, Johnson LA, Lum J, Fong CY, Bongso A, Biswas A, Goh C, Evrard M, Yeo KP, Basu R, Wang JK, Tan Y, Jain R, Tikoo S, Choong C, Weninger W, Poidinger M, Stanley RE, Collin M, Tan NS, Ng LG, Jackson DG, Ginhoux F, Angeli V (2018) Hyaluronan receptor LYVE-1-expressing macrophages maintain arterial tone through hyaluronan-mediated regulation of smooth muscle cell collagen. Immunity 49(326–341):e327.
Lim S, Yoon HY, Park SJ, Song S, Shim MK, Yang S, Kang SW, Lim DK, Kim BS, Moon SH, Kim K (2021) Predicting in vivo therapeutic efficacy of bioorthogonally labeled endothelial progenitor cells in hind limb ischemia models via non-invasive fluorescence molecular tomography. Biomaterials 266:120472. (PMID: 3312020110.1016/j.biomaterials.2020.120472)
Lin YH, Ni XB, Zhang JW, Ou CW, He XQ, Dai WJ, Chen XM, Chen MS (2020) Effect of puerarin on action potential and sodium channel activation in human hypertrophic cardiomyocytes. Biosci Rep 40.
Liu Q, Lu Z, Wang L (2000) Restrictive effect of puerarin on myocardial infarct area in dogs and its possible mechanism. J Tongji Med Univ 20:43–45. (PMID: 12845754)
Liu CM, Ma JQ, Sun YZ (2011) Protective role of puerarin on lead-induced alterations of the hepatic glutathione antioxidant system and hyperlipidemia in rats. Food Chem Toxicol 49:3119–3127. (PMID: 2200117010.1016/j.fct.2011.09.007)
Liu CM, Zheng GH, Ming QL, Sun JM, Cheng C (2013a) Protective effect of puerarin on lead-induced mouse cognitive impairment via altering activities of acetyl cholinesterase, monoamine oxidase and nitric oxide synthase. Environ Toxicol Pharmacol 35:502–510. (PMID: 2350161110.1016/j.etap.2013.02.009)
Liu X, Mei Z, Qian J, Zeng Y, Wang M (2013b) Puerarin partly counteracts the inflammatory response after cerebral ischemia/reperfusion via activating the cholinergic anti-inflammatory pathway. Neural Regen Res 8:3203–3215. (PMID: 252066414146182)
Liu B, Wu Z, Li Y, Ou C, Huang Z, Zhang J, Liu P, Luo C, Chen M (2015a) Puerarin prevents cardiac hypertrophy induced by pressure overload through activation of autophagy. Biochem Biophys Res Commun 464:908–915. (PMID: 2618809410.1016/j.bbrc.2015.07.065)
Liu S, Ren HB, Chen XL, Wang F, Wang RS, Zhou B, Wang C, Sun YX, Wang YJ (2015b) Puerarin attenuates severe burn-induced acute myocardial injury in rats. Burns 41:1748–1757. (PMID: 2651470010.1016/j.burns.2015.06.001)
Liu H, Pathak P, Boehme S, Chiang JL (2016a) Cholesterol 7alpha-hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis. J Lipid Res 57:1831–1844. (PMID: 27534992503636410.1194/jlr.M069807)
Liu X, Ding Y, Zhao B, Liu Y, Luo S, Wu J, Li J, Xiang D (2016b) In vitro and in vivo evaluation of puerarin-loaded PEGylated mesoporous silica nanoparticles. Drug Dev Ind Pharm 42:2031–2037. (PMID: 2728234510.1080/03639045.2016.1190742)
Liu B, Zhao C, Li H, Chen X, Ding Y, Xu S (2018) Puerarin protects against heart failure induced by pressure overload through mitigation of ferroptosis. Biochem Biophys Res Commun 497:233–240. (PMID: 2942765810.1016/j.bbrc.2018.02.061)
Liu H, Zhang X, Zhong X, Li Z, Cai S, Yang P, Ou C, Chen M (2019) Puerarin inhibits vascular calcification of uremic rats. Eur J Pharmacol 855:235–243. (PMID: 3108523710.1016/j.ejphar.2019.05.023)
Liu J, Liu J, Bai M, Wang H (2020a) Protective effect of puerarin against burn-induced heart injury in rats. Exp Ther Med 20:275–282. (PMID: 3253699610.3892/etm.2020.8696)
Liu Z, Jia Y, Song L, Tian Y, Zhang P, Zhang P, Cao Z, Ma J (2020b) Antiarrhythmic effect of crotonoside by regulating sodium and calcium channels in rabbit ventricular myocytes. Life Sci 244:117333. (PMID: 3196213210.1016/j.lfs.2020.117333)
Locatelli L, Cadamuro M, Spirli C, Fiorotto R, Lecchi S, Morell CM, Popov Y, Scirpo R, De Matteis M, Amenduni M, Pietrobattista A, Torre G, Schuppan D, Fabris L, Strazzabosco M (2016) Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis. Hepatology 63:965–982. (PMID: 2664599410.1002/hep.28382)
Lohan SB, Saeidpour S, Colombo M, Staufenbiel S, Unbehauen M, Wolde-Kidan A, Netz RR, Bodmeier R, Haag R, Teutloff C, Bittl R, Meinke MC (2020) Nanocrystals for improved drug delivery of dexamethasone in skin investigated by EPR spectroscopy. Pharmaceutics 12.
Lopez-Royo T, Sebastian V, Moreno-Martinez L, Uson L, Yus C, Alejo T, Zaragoza P, Osta R, Arruebo M, Manzano R (2021) Encapsulation of large-size plasmids in PLGA nanoparticles for gene editing: comparison of three different synthesis methods. Nanomaterials (Basel) 11.
Lu Q, Xiang DX, Yuan HY, Xiao Y, Yuan LQ, Li HB (2014a) Puerarin attenuates calcification of vascular smooth muscle cells. Am J Chin Med 42:337–347. (PMID: 2470786610.1142/S0192415X14500220)
Lu XL, Liu JX, Wu Q, Long SM, Zheng MY, Yao XL, Ren H, Wang YG, Su WW, Fai Cheung RT, Zeng JS, Su H, Pei Z (2014b) Protective effects of puerarin against Ass40-induced vascular dysfunction in zebrafish and human endothelial cells. Eur J Pharmacol 732:76–85. (PMID: 2469026210.1016/j.ejphar.2014.03.030)
Lukas Laws J, Lancaster MC, Ben Shoemaker M, Stevenson WG, Hung RR, Wells Q, Marshall Brinkley D, Hughes S, Anderson K, Roden D, Stevenson LW (2022) Arrhythmias as presentation of genetic cardiomyopathy. Circ Res 130:1698–1722. (PMID: 35617362920561510.1161/CIRCRESAHA.122.319835)
Luo CF, Yuan M, Chen MS, Liu SM, Zhu L, Huang BY, Liu XW, Xiong W (2011) Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration. Int J Pharm 410:138–144. (PMID: 2139256510.1016/j.ijpharm.2011.02.064)
Luo CF, Hou N, Tian J, Yuan M, Liu SM, Xiong LG, Luo JD, Chen MS (2013) Metabolic profile of puerarin in rats after intragastric administration of puerarin solid lipid nanoparticles. Int J Nanomedicine 8:933–940. (PMID: 23486407359251310.2147/IJN.S39349)
Luo X, Zhong B, Hong X, Cui Y, Gao Y, Yin M, Tang M, Hescheler J, Xi J (2016) Puerarin exerts a delayed inhibitory effect on the proliferation of cardiomyocytes derived from murine ES cells via slowing progression through G2/M phase. Cell Physiol Biochem 38:1333–1342. (PMID: 2700850810.1159/000443077)
Luo L, Li Y, Bao Z, Zhu D, Chen G, Li W, Xiao Y, Wang Z, Zhang Y, Liu H, Chen Y, Liao Y, Cheng K, Li Z (2024) Pericardial delivery of SDF-1alpha puerarin hydrogel promotes heart repair and electrical coupling. Adv Mater 36:e2302686. (PMID: 3766579210.1002/adma.202302686)
Ma JQ, Ding J, Zhao H, Liu CM (2014) Puerarin attenuates carbon tetrachloride-induced liver oxidative stress and hyperlipidaemia in mouse by JNK/c-Jun/CYP7A1 pathway. Basic Clin Pharmacol Toxicol 115:389–395. (PMID: 2469856810.1111/bcpt.12245)
Ma Y, Ma Y, Gao M, Han Z, Jiang W, Gu Y, Liu Y (2021a) Platelet-mimicking therapeutic system for noninvasive mitigation of the progression of atherosclerotic plaques. Adv Sci (weinh) 8:2004128. (PMID: 3389819110.1002/advs.202004128)
Ma YH, Shi HJ, Wei QS, Deng QW, Sun JH, Liu Z, Lai BQ, Li G, Ding Y, Niu WT, Zeng YS, Zeng X (2021b) Developing a mechanically matched decellularized spinal cord scaffold for the in situ matrix-based neural repair of spinal cord injury. Biomaterials 279:121192. (PMID: 3470022510.1016/j.biomaterials.2021.121192)
Man MQ, Wakefield JS, Mauro TM, Elias PM (2022) Role of nitric oxide in regulating epidermal permeability barrier function. Exp Dermatol 31:290–298. (PMID: 3466590610.1111/exd.14470)
Martelli A, Citi V, Calderone V (2021) Recent efforts in drug discovery on vascular inflammation and consequent atherosclerosis. Expert Opin Drug Discov 16:411–427. (PMID: 3325648410.1080/17460441.2021.1850688)
Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10:417–426. (PMID: 1219148610.1016/S1097-2765(02)00599-3)
Meng XH, Ni C, Zhu L, Shen YL, Wang LL, Chen YY (2009) Puerarin protects against high glucose-induced acute vascular dysfunction: role of heme oxygenase-1 in rat thoracic aorta. Vascul Pharmacol 50:110–115. (PMID: 1907328110.1016/j.vph.2008.11.003)
Nair AR, Silva SD Jr, Agbor LN, Wu J, Nakagawa P, Mukohda M, Lu KT, Sandgren JA, Pierce GL, Santillan MK, Grobe JL, Sigmund CD (2019) Endothelial PPARgamma (peroxisome proliferator-activated receptor-gamma) protects from angiotensin II-induced endothelial dysfunction in adult offspring born from pregnancies complicated by hypertension. Hypertension 74:173–183. (PMID: 3110456410.1161/HYPERTENSIONAHA.119.13101)
Newman JD, O’Meara E, Bohm M, Savarese G, Kelly PR, Vardeny O, Allen LA, Lancellotti P, Gottlieb SS, Samad Z, Morris AA, Desai NR, Rosano GMC, Teerlink JR, Giraldo CS, Lindenfeld J (2024) Implications of atrial fibrillation for guideline-directed therapy in patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol 83:932–950. (PMID: 3841800810.1016/j.jacc.2023.12.033)
Nguyen Dinh Cat A, Montezano AC, Burger D, Touyz RM (2013) Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxid Redox Signal 19:1110–1120. (PMID: 22530599377154910.1089/ars.2012.4641)
Ni SY, Zhong XL, Li ZH, Huang DJ, Xu WT, Zhou Y, Ou CW, Chen MS (2020) Puerarin Alleviates lipopolysaccharide-induced myocardial fibrosis by inhibiting PARP-1 to prevent HMGB1-mediated TLR4-NF-kappaB signaling pathway. Cardiovasc Toxicol 20:482–491. (PMID: 3223689610.1007/s12012-020-09571-9)
Noh JW, Yang HK, Jun MS, Lee BC (2022) Puerarin attenuates obesity-induced inflammation and dyslipidemia by regulating macrophages and TNF-Alpha in obese mice. Biomedicines 10.
Oeing CU, Jun S, Mishra S, Dunkerly-Eyring BL, Chen A, Grajeda MI, Tahir UA, Gerszten RE, Paolocci N, Ranek MJ, Kass DA (2021) MTORC1-regulated metabolism controlled by TSC2 limits cardiac reperfusion injury. Circ Res 128:639–651. (PMID: 33401933825774810.1161/CIRCRESAHA.120.317710)
Osborn EA, Ughi GJ, Verjans JW, Piao Z, Gerbaud E, Albaghdadi M, Khraishah H, Kassab MB, Takx RAP, Cui J, Mauskapf A, Shen C, Yeh RW, Klimas MT, Tawakol A, Tearney GJ, Jaffer FA (2021) Intravascular molecular-structural assessment of arterial inflammation in preclinical atherosclerosis progression. JACC Cardiovasc Imaging 14:2265–2267. (PMID: 34419392857105710.1016/j.jcmg.2021.06.017)
Ostrakhovitch EA, Tabibzadeh S (2019) Homocysteine and age-associated disorders. Ageing Res Rev 49:144–164. (PMID: 3039175410.1016/j.arr.2018.10.010)
Ott C, Schmieder RE (2022) Diagnosis and treatment of arterial hypertension 2021. Kidney Int 101:36–46. (PMID: 3475712210.1016/j.kint.2021.09.026)
Ou HC, Chou WC, Hung CH, Chu PM, Hsieh PL, Chan SH, Tsai KL (2019) Galectin-3 aggravates ox-LDL-induced endothelial dysfunction through LOX-1 mediated signaling pathway. Environ Toxicol 34:825–835. (PMID: 3096371610.1002/tox.22750)
Ouyang S, Li Y, Wu X, Wang Y, Liu F, Zhang J, Qiu Y, Zhou Z, Wang Z, Xia W, Lin X (2021) GPR4 signaling is essential for the promotion of acid-mediated angiogenic capacity of endothelial progenitor cells by activating STAT3/VEGFA pathway in patients with coronary artery disease. Stem Cell Res Ther 12:149. (PMID: 33632325790586310.1186/s13287-021-02221-z)
Padrela L, Rodrigues MA, Duarte A, Dias AMA, Braga MEM, de Sousa HC (2018) Supercritical carbon dioxide-based technologies for the production of drug nanoparticles/nanocrystals - a comprehensive review. Adv Drug Deliv Rev 131:22–78. (PMID: 3002612710.1016/j.addr.2018.07.010)
Pan HP, Li G (2008) Protecting mechanism of puerarin on the brain neurocyte of rat in acute local ischemia brain injury and local cerebral ischemia-reperfusion injury. Yakugaku Zasshi 128:1689–1698. (PMID: 1898170510.1248/yakushi.128.1689)
Pan B, Fang S, Zhang J, Pan Y, Liu H, Wang Y, Li M, Liu L (2020) Chinese herbal compounds against SARS-CoV-2: puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor. Comput Struct Biotechnol J 18:3518–3527. (PMID: 33200026765701210.1016/j.csbj.2020.11.010)
Pan J, Cao Z, Fang C, Lei Y, Sun J, Huang X, Han D (2021) Huangqi Shengmai Yin ameliorates myocardial fibrosis by activating sirtuin3 and inhibiting TGF-beta/Smad pathway. Front Pharmacol 12:722530. (PMID: 34483934841464410.3389/fphar.2021.722530)
Pedrosa JF, Brant LCC, de Aquino SA, Ribeiro AL, Barreto SM (2021) Segmental evaluation of thoracic aortic calcium and their relations with cardiovascular risk factors in the Brazilian longitudinal study of adult health (ELSA-Brasil). Cells 10.
Pellegrini C, Martelli A, Antonioli L, Fornai M, Blandizzi C, Calderone V (2021) NLRP3 inflammasome in cardiovascular diseases: pathophysiological and pharmacological implications. Med Res Rev 41:1890–1926. (PMID: 3346016210.1002/med.21781)
Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, Goodman SG, Weinshilboum RM, Wang L, Baudhuin LM, Lerman A, Hasan A, Iturriaga E, Fu YP, Geller N, Bailey K, Farkouh ME (2019) Clopidogrel pharmacogenetics. Circ Cardiovasc Interv 12:e007811. (PMID: 3099839610.1161/CIRCINTERVENTIONS.119.007811)
Petsophonsakul P, Furmanik M, Forsythe R, Dweck M, Schurink GW, Natour E, Reutelingsperger C, Jacobs M, Mees B, Schurgers L (2019) Role of vascular smooth muscle cell phenotypic switching and calcification in aortic aneurysm formation. Arterioscler Thromb Vasc Biol 39:1351–1368. (PMID: 3114498910.1161/ATVBAHA.119.312787)
Peyter AC, Armengaud JB, Guillot E, Yzydorczyk C (2021) Endothelial progenitor cells dysfunctions and cardiometabolic disorders: from mechanisms to therapeutic approaches. Int J Mol Sci 22.
Qiao Y, Tang C, Wang Q, Wang D, Yan G, Zhu B (2016) Kir2.1 regulates rat smooth muscle cell proliferation, migration, and post-injury carotid neointimal formation. Biochem Biophys Res Commun 477:774–780. (PMID: 2738723510.1016/j.bbrc.2016.06.134)
Qin H, Zhang Y, Wang R, Du X, Li L, Du H (2016) Puerarin suppresses Na+-K+-ATPase-mediated systemic inflammation and CD36 expression, and alleviates cardiac lipotoxicity in vitro and in vivo. J Cardiovasc Pharmacol 68:465–472. (PMID: 2760693510.1097/FJC.0000000000000431)
Qiu X, Luo J, Fang L (2020) AIBP, angiogenesis, hematopoiesis, and atherogenesis. Curr Atheroscler Rep 23:1. (PMID: 33230630894177310.1007/s11883-020-00899-9)
Quan DQ, Xu GX, Wu XG (2007) Studies on preparation and absolute bioavailability of a self-emulsifying system containing puerarin. Chem Pharm Bull (tokyo) 55:800–803. (PMID: 1747347310.1248/cpb.55.800)
Rafi U, Ahmad S, Bokhari SS, Iqbal MA, Zia A, Khan MA, Roohi N (2021) Association of inflammatory markers/cytokines with cardiovascular risk manifestation in patients with endometriosis. Mediators Inflamm 2021:3425560. (PMID: 34754275857261410.1155/2021/3425560)
Rao M, Wang X, Guo G, Wang L, Chen S, Yin P, Chen K, Chen L, Zhang Z, Chen X, Hu X, Hu S, Song J (2021) Resolving the intertwining of inflammation and fibrosis in human heart failure at single-cell level. Basic Res Cardiol 116:55. (PMID: 3460165410.1007/s00395-021-00897-1)
Reilly L, Alvarado FJ, Lang D, Abozeid S, Van Ert H, Spellman C, Warden J, Makielski JC, Glukhov AV, Eckhardt LL (2020) Genetic loss of IK1 causes adrenergic-induced phase 3 early afterdepolariz ations and polymorphic and bidirectional ventricular tachycardia. Circ Arrhythm Electrophysiol 13:e008638. (PMID: 32931337757495410.1161/CIRCEP.120.008638)
Revelo XS, Parthiban P, Chen C, Barrow F, Fredrickson G, Wang H, Yucel D, Herman A, van Berlo JH (2021) Cardiac resident macrophages prevent fibrosis and stimulate angiogenesis. Circ Res 129:1086–1101. (PMID: 34645281863882210.1161/CIRCRESAHA.121.319737)
Robinson VM, Alsalahat I, Freeman S, Antzelevitch C, Barajas-Martinez H, Venetucci L (2022) A carvedilol analogue, VK-II-86, prevents hypokalaemia-induced ventricular arrhythmia through novel multi-channel effects. Br J Pharmacol 179:2713–2732. (PMID: 3487765110.1111/bph.15775)
Rookyard AW, Paulech J, Thyssen S, Liddy KA, Puckeridge M, Li DK, White MY, Cordwell SJ (2021) A Global profile of reversible and irreversible cysteine redox post-translational modifications during myocardial ischemia/reperfusion injury and antioxidant intervention. Antioxid Redox Signal 34:11–31. (PMID: 3272933910.1089/ars.2019.7765)
Ross R (1999) Atherosclerosis–an inflammatory disease. N Engl J Med 340:115–126. (PMID: 988716410.1056/NEJM199901143400207)
Senter E, Vrooman H, Shartle K (2022) Role of income-lifting social programs in reducing years of life lost to myocardial infarction and sudden death. JAMA Cardiol 7:230. (PMID: 3491007910.1001/jamacardio.2021.5127)
Shah M, He Z, Rauf A, Beikoghli Kalkhoran S, Heiestad CM, Stenslokken KO, Parish CR, Soehnlein O, Arjun S, Davidson SM, Yellon D (2022) Extracellular histones are a target in myocardial ischaemia-reperfusion injury. Cardiovasc Res 118:1115–1125. (PMID: 3387818310.1093/cvr/cvab139)
Shen XY, Gao ZK, Han Y, Yuan M, Guo YS, Bi X (2021) Activation and role of astrocytes in ischemic stroke. Front Cell Neurosci 15:755955. (PMID: 3486720110.3389/fncel.2021.755955)
Shi W, Yuan R, Chen X, Xin Q, Wang Y, Shang X, Cong W, Chen K (2019) Puerarin reduces blood pressure in spontaneously hypertensive rats by targeting eNOS. Am J Chin Med 47:19–38. (PMID: 3061245710.1142/S0192415X19500022)
Shibata S (2008) Retrospective aspect of modern pharmaceutical studies in Japan and memory of my life working in pharmaceutical science. Yakushigaku Zasshi 43:122–127. (PMID: 19579822)
Simon A, Plies L, Habermeier A, Martine U, Reining M, Closs EI (2003) Role of neutral amino acid transport and protein breakdown for substrate supply of nitric oxide synthase in human endothelial cells. Circ Res 93:813–820. (PMID: 1451244410.1161/01.RES.0000097761.19223.0D)
Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, Boren J (2002) Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417:750–754. (PMID: 1206618710.1038/nature00804)
Soehnlein O, Libby P (2021) Targeting inflammation in atherosclerosis - from experimental insights to the clinic. Nat Rev Drug Discov 20:589–610. (PMID: 33976384811247610.1038/s41573-021-00198-1)
Souilhol C, Harmsen MC, Evans PC, Krenning G (2018) Endothelial-mesenchymal transition in atherosclerosis. Cardiovasc Res 114:565–577. (PMID: 2930952610.1093/cvr/cvx253)
Sun XH, Ding JP, Li H, Pan N, Gan L, Yang XL, Xu HB (2007) Activation of large-conductance calcium-activated potassium channels by puerarin: the underlying mechanism of puerarin-mediated vasodilation. J Pharmacol Exp Ther 323:391–397. (PMID: 1765263410.1124/jpet.107.125567)
Takahashi M (2022) NLRP3 inflammasome as a key driver of vascular disease. Cardiovasc Res 118:372–385. (PMID: 3348373210.1093/cvr/cvab010)
Tang TT, Hu XB, Liao DH, Liu XY, Xiang DX (2013) Mechanisms of microemulsion enhancing the oral bioavailability of puerarin: comparison between oil-in-water and water-in-oil microemulsions using the single-pass intestinal perfusion method and a chylomicron flow blocking approach. Int J Nanomedicine 8:4415–4426. (PMID: 24277986383801710.2147/IJN.S51469)
Tang H, Song X, Ling Y, Wang X, Yang P, Luo T, Chen A (2017) Puerarin attenuates myocardial hypoxia/reoxygenation injury by inhibiting autophagy via the Akt signaling pathway. Mol Med Rep 15:3747–3754. (PMID: 2839320910.3892/mmr.2017.6424)
Taniyama Y, Griendling KK (2003) Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 42:1075–1081. (PMID: 1458129510.1161/01.HYP.0000100443.09293.4F)
Tao HQ, Meng Q, Li MH, Yu H, Liu MF, Du D, Sun SL, Yang HC, Wang YM, Ye W, Yang LZ, Zhu DL, Jiang CL, Peng HS (2013) HP-beta-CD-PLGA nanoparticles improve the penetration and bioavailability of puerarin and enhance the therapeutic effects on brain ischemia-reperfusion injury in rats. Naunyn Schmiedebergs Arch Pharmacol 386:61–70. (PMID: 2319228410.1007/s00210-012-0804-5)
Tao Z, Ge Y, Zhou N, Wang Y, Cheng W, Yang Z (2016) Puerarin inhibits cardiac fibrosis via monocyte chemoattractant protein (MCP)-1 and the transforming growth factor-beta1 (TGF-beta1) pathway in myocardial infarction mice. Am J Transl Res 8:4425–4433. (PMID: 278300265095335)
Telange DR, Jain SP, Pethe AM, Kharkar PS, Rarokar NR (2021) Use of combined nanocarrier system based on chitosan nanoparticles and phospholipids complex for improved delivery of ferulic acid. Int J Biol Macromol 171:288–307. (PMID: 3341804610.1016/j.ijbiomac.2020.12.211)
Toyoda K, Yoshimura S, Nakai M, Koga M, Sasahara Y, Sonoda K, Kamiyama K, Yazawa Y, Kawada S, Sasaki M, Terasaki T, Miwa K, Koge J, Ishigami A, Wada S, Iwanaga Y, Miyamoto Y, Minematsu K, Kobayashi S, Bank Japan Stroke Data, I, (2022) Twenty-year change in severity and outcome of ischemic and hemorrhagic strokes. JAMA Neurol 79:61–69. (PMID: 3487068910.1001/jamaneurol.2021.4346)
Travers JG, Tharp CA, Rubino M, McKinsey TA (2022) Therapeutic targets for cardiac fibrosis: from old school to next-gen. J Clin Invest 132.
Tu L, Yi Y, Wu W, Hu F, Hu K, Feng J (2013) Effects of particle size on the pharmacokinetics of puerarin nanocrystals and microcrystals after oral administration to rat. Int J Pharm 458:135–140. (PMID: 2412072910.1016/j.ijpharm.2013.10.001)
Tu L, Cheng M, Sun Y, Fang Y, Liu J, Liu W, Feng J, Jin Y (2020) Fabrication of ultra-small nanocrystals by formation of hydrogen bonds: in vitro and in vivo evaluation. Int J Pharm 573:118730. (PMID: 3170597210.1016/j.ijpharm.2019.118730)
Vanchin B, Sol M, Gjaltema RAF, Brinker M, Kiers B, Pereira AC, Harmsen MC, Moonen JAJ, Krenning G (2021) Reciprocal regulation of endothelial-mesenchymal transition by MAPK7 and EZH2 in intimal hyperplasia and coronary artery disease. Sci Rep 11:17764. (PMID: 34493753842379510.1038/s41598-021-97127-4)
Vasan RS, Enserro DM, Beiser AS, Xanthakis V (2022) Lifetime risk of heart failure among participants in the Framingham study. J Am Coll Cardiol 79:250–263. (PMID: 35057911882063810.1016/j.jacc.2021.10.043)
Wan H, Zhu H, Tian M, Hu X, Yang J, Zhao C, Zhang H (2008) Protective effect of chuanxiongzine-puerarin in a rat model of transient middle cerebral artery occlusion-induced focal cerebral ischemia. Nucl Med Commun 29:1113–1122. (PMID: 1898753410.1097/MNM.0b013e3283108995)
Wan Q, Liu Z, Yang Y (2018) Puerarin inhibits vascular smooth muscle cells proliferation induced by fine particulate matter via suppressing of the p38 MAPK signaling pathway. BMC Complement Altern Med 18:146. (PMID: 29728095593593410.1186/s12906-018-2206-9)
Wang K, Zhu X, Zhang K, Yao Y, Zhuang M, Tan C, Zhou F, Zhu L (2017a) Puerarin inhibits amyloid beta-induced NLRP3 inflammasome activation in retinal pigment epithelial cells via suppressing ROS-dependent oxidative and endoplasmic reticulum stresses. Exp Cell Res 357:335–340. (PMID: 2858376210.1016/j.yexcr.2017.05.030)
Wang TM, Chen KC, Hsu PY, Lin HF, Wang YS, Chen CY, Liao YC, Juo SH (2017b) microRNA let-7g suppresses PDGF-induced conversion of vascular smooth muscle cell into the synthetic phenotype. J Cell Mol Med 21:3592–3601. (PMID: 28699690570659110.1111/jcmm.13269)
Wang C, Niimi M, Watanabe T, Wang Y, Liang J, Fan J (2018) Treatment of atherosclerosis by traditional Chinese medicine: questions and quandaries. Atherosclerosis 277:136–144. (PMID: 3021268210.1016/j.atherosclerosis.2018.08.039)
Wang M, Xu H, Li Y, Cao C, Zhu H, Wang Y, Zhao Z, Pei G, Zhu F, Yang Q, Deng X, Zhou C, Guo Y, Wu J, Liao W, Yang J, Yao Y, Zeng R (2020a) Exogenous bone marrow derived-putative endothelial progenitor cells attenuate ischemia reperfusion-induced vascular injury and renal fibrosis in mice dependent on pericytes. Theranostics 10:12144–12157. (PMID: 33204334766768810.7150/thno.48562)
Wang S, Zhang S, Wang S, Gao P, Dai L (2020b) A comprehensive review on Pueraria: insights on its chemistry and medicinal value. Biomed Pharmacother 131:110734. (PMID: 3294215810.1016/j.biopha.2020.110734)
Wang ZK, Chen RR, Li JH, Chen JY, Li W, Niu XL, Wang FF, Wang J, Yang JX (2020c) Puerarin protects against myocardial ischemia/reperfusion injury by inhibiting inflammation and the NLRP3 inflammasome: the role of the SIRT1/NF-kappaB pathway. Int Immunopharmacol 89:107086. (PMID: 3306886810.1016/j.intimp.2020.107086)
Wang H, Li Y, Min Y, Zhang H, Hao L, Zhang R, Jiang Y, Song Y (2021) Preparation and properties of pue-loaded HA-ADH-PS nanomicelles. Des Monomers Polym 24:1–12. (PMID: 33536833783203210.1080/15685551.2020.1860481)
Wei S, Tong J, Xue Q, Liu Y, Xu X (2017) Effect of puerarin on transcriptome of astrocyte during oxygen-glucose deprivation/reoxygenation injury. Mol Cell Biochem 425:113–123. (PMID: 2784425210.1007/s11010-016-2867-y)
Wijaya CJ, Ismadji S, Gunawan S (2021) A review of lignocellulosic-derived nanoparticles for drug delivery applications: lignin nanoparticles, xylan nanoparticles, and cellulose nanocrystals. Molecules 26.
Wolf D, Ley K (2019) Immunity and inflammation in atherosclerosis. Circ Res 124:315–327. (PMID: 30653442634248210.1161/CIRCRESAHA.118.313591)
Wu H, Lu C, Zhou A, Min Z, Zhang Y (2009) Enhanced oral bioavailability of puerarin using microemulsion vehicle. Drug Dev Ind Pharm 35:138–144. (PMID: 1904018010.1080/03639040801973495)
Wu M, Liang S, Ma L, Han Y, Zhang X, Xu C (2014a) Effects of delayed puerarin treatment in long-term neurological outcomes of focal ischemic stroke in rats. Indian J Pharmacol 46:157–160. (PMID: 2474118510.4103/0253-7613.129305)
Wu XD, Wang C, Zhang ZY, Fu Y, Liu FY, Liu XH (2014b) Puerarin attenuates cerebral damage by improving cerebral microcirculation in spontaneously hypertensive rats. Evid Based Complement Alternat Med 2014:408501. (PMID: 2471593010.1155/2014/408501)
Wu JY, Li YJ, Han M, Hu XB, Yang L, Wang JM, Xiang DX (2018) A microemulsion of puerarin-phospholipid complex for improving bioavailability: preparation, in vitro and in vivo evaluations. Drug Dev Ind Pharm 44:1336–1341. (PMID: 2951304610.1080/03639045.2018.1449856)
Wu JY, Li YJ, Liu XY, Cai JX, Hu XB, Wang JM, Tang TT, Xiang DX (2019a) 3,5,4’-trimethoxy-trans-stilbene loaded PEG-PE micelles for the treatment of colon cancer. Int J Nanomedicine 14:7489–7502. (PMID: 3157186010.2147/IJN.S221625)
Wu K, Xiu Y, Zhou P, Qiu Y, Li Y (2019b) A new use for an old drug: carmofur attenuates lipopolysaccharide (LPS)-induced acute lung injury via inhibition of FAAH and NAAA activities. Front Pharmacol 10:818. (PMID: 3137958310.3389/fphar.2019.00818)
Wu J, Li S, Li C, Cui L, Ma J, Hui Y (2021a) The non-canonical effects of heme oxygenase-1, a classical fighter against oxidative stress. Redox Biol 47:102170. (PMID: 3468815610.1016/j.redox.2021.102170)
Wu X, Li Y, Zhang S, Zhou X (2021b) Ferroptosis as a novel therapeutic target for cardiovascular disease. Theranostics 11:3052–3059. (PMID: 3353707310.7150/thno.54113)
Xia X, Hu T, He J, Xu Q, Yu C, Liu X, Shao Z, Liao Y, Huang H, Liu N (2020a) USP10 deletion inhibits macrophage-derived foam cell formation and cellular-oxidized low density lipoprotein uptake by promoting the degradation of CD36. Aging (albany NY) 12:22892–22905. (PMID: 33197885)
Xia X, Xu Q, Liu M, Chen X, Liu X, He J, Hu T, Yu C, Huang H, Liu S, Liu N (2020b) Deubiquitination of CD36 by UCHL1 promotes foam cell formation. Cell Death Dis 11:636. (PMID: 3280129910.1038/s41419-020-02888-x)
Xiao PT, Xie ZS, Kuang YJ, Liu SY, Zeng C, Li P, Liu EH (2021) Discovery of a potent FKBP38 agonist that ameliorates HFD-induced hyperlipidemia via mTOR/P70S6K/SREBPs pathway. Acta Pharm Sin B 11:3542–3552. (PMID: 34900535864243610.1016/j.apsb.2021.03.031)
Xiong Y, Wakhloo AK, Fisher M (2022) Advances in acute ischemic stroke therapy. Circ Res 130:1230–1251. (PMID: 3542091910.1161/CIRCRESAHA.121.319948)
Xu H, Zhao M, Liang S, Huang Q, Xiao Y, Ye L, Wang Q, He L, Ma L, Zhang H, Zhang L, Jiang H, Ke X, Gu Y (2016) The effects of puerarin on rat ventricular myocytes and the potential mechanism. Sci Rep 6:35475. (PMID: 27762288507187310.1038/srep35475)
Xu HX, Pan W, Qian JF, Liu F, Dong HQ, Liu QJ (2019a) MicroRNA21 contributes to the puerarininduced cardioprotection via suppression of apoptosis and oxidative stress in a cell model of ischemia/reperfusion injury. Mol Med Rep 20:719–727. (PMID: 31115556)
Xu X, Jiang R, Chen M, Dong M, Liu Q, Cheng H, Zhou K, Chen L, Li M, Jiang C (2019b) Puerarin decreases collagen secretion in AngII-induced atrial fibroblasts through inhibiting autophagy via the JNK-Akt-mTOR signaling pathway. J Cardiovasc Pharmacol 73:373–382. (PMID: 3116224610.1097/FJC.0000000000000672)
Xu K, Liu X, Yin D, Ren G, Zhao Y (2020) PP2A alleviates oxidized LDL-induced endothelial dysfunction by regulating LOX-1/ROS/MAPK axis. Life Sci 243:117270. (PMID: 3192342110.1016/j.lfs.2020.117270)
Yan LP, Chan SW, Chan AS, Chen SL, Ma XJ, Xu HX (2006) Puerarin decreases serum total cholesterol and enhances thoracic aorta endothelial nitric oxide synthase expression in diet-induced hypercholesterolemic rats. Life Sci 79:324–330. (PMID: 1647282310.1016/j.lfs.2006.01.016)
Yan LP, Zhuang YL, Chan SW, Chen SL, Shi GG (2009) Analysis of the mechanisms underlying the endothelium-dependent antivasoconstriction of puerarin in rat aorta. Naunyn Schmiedebergs Arch Pharmacol 379:587–597. (PMID: 1919089410.1007/s00210-008-0388-2)
Yan J, Honglei Y, Yun W, Sheng D, Yun H, Anhua Z, Na F, Min L, Dandan S, Jing W, Junming T, Wenjun Z, Xiju H (2022) Puerarin ameliorates myocardial remodeling of spontaneously hypertensive rats through inhibiting TRPC6-CaN-NFATc3 pathway. Eur J Pharmacol 933:175254. (PMID: 3608769610.1016/j.ejphar.2022.175254)
Yang X, Hu W, Zhang Q, Wang Y, Sun L (2010) Puerarin inhibits C-reactive protein expression via suppression of nuclear factor kappaB activation in lipopolysaccharide-induced peripheral blood mononuclear cells of patients with stable angina pectoris. Basic Clin Pharmacol Toxicol 107:637–642. (PMID: 2034605910.1111/j.1742-7843.2010.00548.x)
Yang M, Luo Y, Liu T, Zhong X, Yan J, Huang Q, Tao J, He Q, Guo M, Hu Y (2018) The effect of puerarin on carotid intima-media thickness in patients with active rheumatoid arthritis: a randomized controlled trial. Clin Ther 40(1752–1764):e1751.
Yang D, Wan X, Dennis AT, Bektik E, Wang Z, Costa MGS, Fagnen C, Venien-Bryan C, Xu X, Gratz DH, Hund TJ, Mohler PJ, Laurita KR, Deschenes I, Fu JD (2021) MicroRNA biophysically modulates cardiac action potential by direct binding to ion channel. Circulation 143:1597–1613. (PMID: 33590773813231310.1161/CIRCULATIONAHA.120.050098)
Yao YS, Li TD, Zeng ZH (2020) Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review. Lipids Health Dis 19:23. (PMID: 32035485700767910.1186/s12944-019-1171-8)
Yi T, Tang D, Wang F, Zhang J, Zhang J, Wang J, Xu X, Zhang J (2017) Enhancing both oral bioavailability and brain penetration of puerarin using borneol in combination with preparation technologies. Drug Deliv 24:422–429. (PMID: 28165806824115210.1080/10717544.2016.1259372)
Yu A, Wang H, Wang J, Cao F, Gao Y, Cui J, Zhai G (2011) Formulation optimization and bioavailability after oral and nasal administration in rabbits of puerarin-loaded microemulsion. J Pharm Sci 100:933–941. (PMID: 2086277610.1002/jps.22333)
Yu XH, Chen JJ, Deng WY, Xu XD, Liu QX, Shi MW, Ren K (2020) Biochanin A mitigates atherosclerosis by inhibiting lipid accumulation and inflammatory response. Oxid Med Cell Longev 2020:8965047. (PMID: 33959213807455010.1155/2020/8965047)
Yu ZM, Wan XM, Xiao M, Zheng C, Zhou XL (2021) Puerarin induces Nrf2 as a cytoprotective mechanism to prevent cadmium-induced autophagy inhibition and NLRP3 inflammasome activation in AML12 hepatic cells. J Inorg Biochem 217:111389. (PMID: 3360753910.1016/j.jinorgbio.2021.111389)
Yuan Y, Zong J, Zhou H, Bian ZY, Deng W, Dai J, Gan HW, Yang Z, Li H, Tang QZ (2014) Puerarin attenuates pressure overload-induced cardiac hypertrophy. J Cardiol 63:73–81. (PMID: 2390653010.1016/j.jjcc.2013.06.008)
Yuan Y, Zhou H, Wu QQ, Li FF, Bian ZY, Deng W, Zhou MQ, Tang QZ (2016) Puerarin attenuates the inflammatory response and apoptosis in LPS-stimulated cardiomyocytes. Exp Ther Med 11:415–420. (PMID: 2689362410.3892/etm.2015.2910)
Zeitler EP, Poole JE, Albert CM, Al-Khatib SM, Ali-Ahmed F, Birgersdotter-Green U, Cha YM, Chung MK, Curtis AB, Hurwitz JL, Lampert R, Sandhu RK, Shaik F, Sullivan E, Tamirisa KP, Santos Volgman A, Wright JM, Russo AM (2022) Arrhythmias in female patients: incidence, presentation and management. Circ Res 130:474–495. (PMID: 3517583910.1161/CIRCRESAHA.121.319893)
Zhai X, Qiao X, Zhang L, Wang D, Zhang L, Feng Q, Wu B, Cao J, Liu Q (2019) IK1 channel agonist zacopride suppresses ventricular arrhythmias in conscious rats with healing myocardial infarction. Life Sci 239:117075. (PMID: 3175158710.1016/j.lfs.2019.117075)
Zhang L (2019) Pharmacokinetics and drug delivery systems for puerarin, a bioactive flavone from traditional Chinese medicine. Drug Deliv 26:860–869. (PMID: 31524010675860510.1080/10717544.2019.1660732)
Zhang S, Chen S, Shen Y, Yang D, Liu X, Sun-Chi AC, Xu H (2006) Puerarin induces angiogenesis in myocardium of rat with myocardial infarction. Biol Pharm Bull 29:945–950. (PMID: 1665172410.1248/bpb.29.945)
Zhang SY, Chen G, Wei PF, Huang XS, Dai Y, Shen YJ, Chen SL, Sun-Chi CA, Xu HX (2008) The effect of puerarin on serum nitric oxide concentration and myocardial eNOS expression in rats with myocardial infarction. J Asian Nat Prod Res 10:373–381. (PMID: 1834806310.1080/10286020801892250)
Zhang H, Zhang L, Zhang Q, Yang X, Yu J, Shun S, Wu Y, Zeng Q, Wang T (2011a) Puerarin: a novel antagonist to inward rectifier potassium channel (IK1). Mol Cell Biochem 352:117–123. (PMID: 2132754510.1007/s11010-011-0746-0)
Zhang NB, Huang ZG, Cui WD, Ding BP (2011b) Effects of puerarin on expression of cardiac Smad3 and Smad7 mRNA in spontaneously hypertensive rat. J Ethnopharmacol 138:737–740. (PMID: 2202744710.1016/j.jep.2011.10.013)
Zhang Y, Wang R, Wu J, Shen Q (2012) Characterization and evaluation of self-microemulsifying sustained-release pellet formulation of puerarin for oral delivery. Int J Pharm 427:337–344. (PMID: 2236638110.1016/j.ijpharm.2012.02.013)
Zhang H, Zhai Z, Zhou H, Li Y, Li X, Lin Y, Li W, Shi Y, Zhou MS (2015) Puerarin inhibits oxLDL-induced macrophage activation and foam cell formation in human THP1 macrophage. Biomed Res Int 2015:403616. (PMID: 2657642110.1155/2015/403616)
Zhang X, Liu Y, Han Q (2016) Puerarin attenuates cardiac hypertrophy partly through increasing Mir-15b/195 expression and suppressing non-canonical transforming growth factor beta (Tgfbeta) signal pathway. Med Sci Monit 22:1516–1523. (PMID: 2714579010.12659/MSM.895877)
Zhang S, Chen L, Zhou Z, Fan W, Liu S (2019) Effects of puerarin on clinical parameters, vascular endothelial function, and inflammatory factors in patients with coronary artery disease. Med Sci Monit 25:402–408. (PMID: 3063676810.12659/MSM.911108)
Zhang Y, Wu G, Zhang Y, Wang X, Jin Q, Zhang H (2020) Advances in exogenous docosahexaenoic acid-containing phospholipids: sources, positional isomerism, biological activities, and advantages. Compr Rev Food Sci Food Saf 19:1420–1448. (PMID: 3333709410.1111/1541-4337.12543)
Zhang J, Chen Y, Gao W (2021) Puerarin protects against human retinal endothelial cells injury induced by high glucose via regulating miR-16-5p/CASP1 axis. Gen Physiol Biophys 40:235–243. (PMID: 3410037910.4149/gpb_2021010)
Zhang Y, Xin L, Xiang M, Shang C, Wang Y, Wang Y, Cui X, Lu Y (2022) The molecular mechanisms of ferroptosis and its role in cardiovascular disease. Biomed Pharmacother 145:112423. (PMID: 3480078310.1016/j.biopha.2021.112423)
Zhao GJ, Hou N, Cai SA, Liu XW, Li AQ, Cheng CF, Huang Y, Li LR, Mai YP, Liu SM, Ou CW, Xiong ZY, Chen XH, Chen MS, Luo CF (2018) Contributions of Nrf2 to puerarin prevention of cardiac hypertrophy and its metabolic enzymes expression in rats. J Pharmacol Exp Ther 366:458–469. (PMID: 2994593010.1124/jpet.118.248369)
Zhao L, Wang L, Zhang D, Chen Y, Jin F (2021a) Puerarin alleviates coronary heart disease via suppressing inflammation in a rat model. Gene 771:145354. (PMID: 3333321510.1016/j.gene.2020.145354)
Zhao W, Zhao J, Zhang X, Fan N, Rong J (2021b) Upregulation of small ubiquitin-like modifier 2 and protein SUMOylation as a cardioprotective mechanism against myocardial ischemia-reperfusion injury. Front Pharmacol 12:731980. (PMID: 34588985847370710.3389/fphar.2021.731980)
Zhao F, Fan S, Ghate D, Romanova S, Bronich TK, Zhao S (2022) A hydrogel ionic circuit based high-intensity iontophoresis device for intraocular macromolecule and nanoparticle delivery. Adv Mater 34:e2107315. (PMID: 3471672910.1002/adma.202107315)
Zhou F, Wang L, Liu P, Hu W, Zhu X, Shen H, Yao Y (2014) Puerarin protects brain tissue against cerebral ischemia/reperfusion injury by inhibiting the inflammatory response. Neural Regen Res 9:2074–2080. (PMID: 25657724431647210.4103/1673-5374.147934)
Zhou E, Hoeke G, Li Z, Eibergen AC, Schonk AW, Koehorst M, Boverhof R, Havinga R, Kuipers F, Coskun T, Boon MR, Groen AK, Rensen PCN, Berbee JFP, Wang Y (2020a) Colesevelam enhances the beneficial effects of brown fat activation on hyperlipidaemia and atherosclerosis development. Cardiovasc Res 116:1710–1720. (PMID: 3158931810.1093/cvr/cvz253)
Zhou T, Wang Z, Guo M, Zhang K, Geng L, Mao A, Yang Y, Yu F (2020b) Puerarin induces mouse mesenteric vasodilation and ameliorates hypertension involving endothelial TRPV4 channels. Food Funct 11:10137–10148. (PMID: 3315559910.1039/D0FO02356F)
Zhou Y, Li M, Song J, Shi Y, Qin X, Gao Z, Lv Y, Du G (2020c) The cardioprotective effects of the new crystal form of puerarin in isoproterenol-induced myocardial ischemia rats based on metabolomics. Sci Rep 10:17787. (PMID: 33082379757558310.1038/s41598-020-74246-y)
Zhou YX, Zhang H, Peng C (2021) Effects of puerarin on the prevention and treatment of cardiovascular diseases. Front Pharmacol 12:771793. (PMID: 34950032868913410.3389/fphar.2021.771793)
Zhou B, Zhang J, Chen Y, Liu Y, Tang X, Xia P, Yu P, Yu S (2022) Puerarin protects against sepsis-induced myocardial injury through AMPK-mediated ferroptosis signaling. Aging (albany NY) 14:3617–3632. (PMID: 3548244010.18632/aging.204033)
Zhu JH, Wang XX, Chen JZ, Shang YP, Zhu JH, Guo XG, Sun J (2004) Effects of puerarin on number and activity of endothelial progenitor cells from peripheral blood. Acta Pharmacol Sin 25:1045–1051. (PMID: 15301738)
Zhu J, Wang X, Shang Y, Xie X, Zhang F, Chen J, Fu G (2008) Puerarin reduces endothelial progenitor cells senescence through augmentation of telomerase activity. Vascul Pharmacol 49:106–110. (PMID: 1869259610.1016/j.vph.2008.07.002)
Zhu LH, Wang L, Wang D, Jiang H, Tang QZ, Yan L, Bian ZY, Wang XA, Li H (2010) Puerarin attenuates high-glucose-and diabetes-induced vascular smooth muscle cell proliferation by blocking PKCbeta2/Rac1-dependent signaling. Free Radic Biol Med 48:471–482. (PMID: 1985426510.1016/j.freeradbiomed.2009.10.040)
Zhu ML, Wang G, Wang H, Guo YM, Song P, Xu J, Li P, Wang S, Yang L (2019) Amorphous nano-selenium quantum dots improve endothelial dysfunction in rats and prevent atherosclerosis in mice through Na(+)/H(+) exchanger 1 inhibition. Vascul Pharmacol 115:26–32. (PMID: 3069573010.1016/j.vph.2019.01.005)
Zhu T, Kang W, Yang H, Li Z, Zhou B, He Y, Wang J, Aidarova S, Sarsenbekuly B (2022a) Advances of microemulsion and its applications for improved oil recovery. Adv Colloid Interface Sci 299:102527. (PMID: 3460765210.1016/j.cis.2021.102527)
Zhu Y, Sun Y, Hu J, Pan Z (2022b) Insight into the mechanism of exercise preconditioning in ischemic stroke. Front Pharmacol 13:866360. (PMID: 35350755895788610.3389/fphar.2022.866360)
Zhuang T, Liu J, Chen X, Zhang L, Pi J, Sun H, Li L, Bauer R, Wang H, Yu Z, Zhang Q, Tomlinson B, Chan P, Zheng X, Morrisey E, Liu Z, Reilly M, Zhang Y (2019) Endothelial Foxp1 suppresses atherosclerosis via modulation of Nlrp3 inflammasome activation. Circ Res 125:590–605. (PMID: 3131865810.1161/CIRCRESAHA.118.314402)
Zhuang L, Jia K, Chen C, Li Z, Zhao J, Hu J, Zhang H, Fan Q, Huang C, Xie H, Lu L, Shen W, Ning G, Wang J, Zhang R, Chen K, Yan X (2022) DYRK1B-STAT3 drives cardiac hypertrophy and heart failure by impairing mitochondrial bioenergetics. Circulation 145:829–846. (PMID: 3523534310.1161/CIRCULATIONAHA.121.055727)
Ziegler T, Abdel Rahman F, Jurisch V, Kupatt C (2019) Atherosclerosis and the capillary network; pathophysiology and potential therapeutic strategies. Cells 9.
Zou H, Ming B, Li J, Xiao Y, Lai L, Gao M, Xu Y, Tan Z, Gong F, Zheng F (2021) Extracellular HMGB1 contributes to the chronic cardiac allograft vasculopathy/fibrosis by modulating TGF-beta1 signaling. Front Immunol 12:641973. (PMID: 33777037798822210.3389/fimmu.2021.641973)

Keywords: Cardiovascular diseases; Molecular targets; Puerarin; Therapeutic mechanisms

0 (Isoflavones)
Z9W8997416 (puerarin)
0 (Vasodilator Agents)

Date Created: 20240506 Date Completed: 20241003 Latest Revision: 20241003

20241004

10.1007/s00210-024-03142-3

38709267